CAR-T cells for blood cancers with plasma cell features
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new type of CAR-T cell therapy that targets two markers (CD19 and BCMA) on cancer cells. It is for people with certain blood cancers like multiple myeloma or lymphoma that have not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a blood cancer that tests positive for CD19 or BCMA markers.
- You need to have tried at least 3 prior treatments (or 2 for a specific type called light chain amyloidosis) and they stopped working.
- You must be between 18 and 80 years old.
- You should be in fairly good health, able to care for yourself (ECOG score 0–2), and expected to live at least 3 more months.
- Your heart, lungs, and liver must work well enough, and your hemoglobin level must be at least 60 g/L.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell treatment that targets both CD19 and BCMA proteins on cancer cells. It may help people with multiple myeloma, plasma cell leukemia, or related cancers that have not responded to at least three prior treatments.
This trial tests a new type of cell therapy called CAR-T cells that are designed to recognize and attack cancer cells in patients with multiple myeloma, plasmacytoma, plasma cell leukemia, or light chain amyloidosis that have not responded well to previous treatments. The goal is to see if this approach can help patients whose cancers have become resistant to standard medicines.
This trial tests a new immune cell therapy (CAR-T) that targets two markers on high-risk plasma cell cancers. It aims to see if this treatment is safe and helpful for people with aggressive or resistant forms of this disease.
This trial tests a combination of drugs (bortezomib, lenalidomide, and dexamethasone) followed by a special cell therapy called CAR-T that targets a protein (BCMA) on cancer cells. It is for people with a rare and aggressive blood cancer called primary plasma cell leukemia who are not able to have a stem cell transplant.
This trial tests a new CAR-T therapy designed to target specific proteins on cancer cells. It may be an option for people with advanced blood cancers (like multiple myeloma or lymphoma) or solid tumors (like small cell lung cancer) that have not responded to other treatments.
This study tests a new kind of CAR-T cell therapy for people with certain types of B-cell lymphoma that have come back or not improved after standard treatments. The CAR-T cells have been modified to turn off two genes (BCOR and ZC3H12) to make them work better against the cancer.
Hear when a new Relapsed or Refractory Plasma Cell Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.